Search
Tolazoline
go.drugbank.com/drugs/DB00797ApprovedVet approvedWithdrawnTolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear.
Modified vaccinia ankara
go.drugbank.com/drugs/DB15483ApprovedInvestigationalModified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnLike all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified as a second generation protease inhibitor. … This class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs.
Zopapogene imadenovec
go.drugbank.com/drugs/DB24672ApprovedInvestigational[L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP. … Recurrent respiratory papillomatosis (RRP) is a rare, debilitating disease driven by chronic human papillomavirus (HPV) 6 or 11 infection and characterized by recurrent benign tumors in the respiratory
Cholecalciferol
go.drugbank.com/drugs/DB00169ApprovedInvestigationalNutraceuticalAppropriate levels of vitamin D must be upheld in the body in order to maintain calcium and phosphorus levels in a healthy physiologic range to sustain a variety of metabolic functions, transcription regulation … However, studies are also ongoing to determine whether or not cholecalciferol may also play certain roles in cancer, autoimmune disorders, cardiovascular disease, and other medical conditions that may
Mixtures: T-PA Cap, TL-SelectMavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4. … by a reduced number of mature neutrophils and lymphocytes.
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [A20298,A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage
Safrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnIn 1960, it was used as an antidepressant but it is now discontinued.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational[A20343] Improvements in lung function (ppFEV1) were found to be statistically significant, but minimal, with only a 2.6-3.0% change from baseline with more than 70% of patients failing to achieve an absolute … and trafficking of mature protein to the cell surface.
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalDefects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red blood cells, leading to lifelong premature destruction of red blood cells or chronic … It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells.